Clinical Trials for Stomach Cancer

Ramucirumab Plus Trifluridine/Tipiracil (TAS-102) for Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-Inferiority Phase 2 Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with unresectable or metastatic gastric/GEJ adenocarcinoma progressing after fluoropyrimidine/platinum (and trastuzumab if HER2+) are randomized to ramucirumab (VEGFR-2 antibody) plus oral trifluridine/tipiracil (TAS-102, nucleoside analog with thymidine phosphorylase inhibitor) versus the standard ramucirumab plus paclitaxel as second-line therapy. Key eligibility: ECOG 0–1, adequate organ function, no prior ramucirumab/TAS-102 or recent taxane exposure, and ability to take oral therapy.

ClinicalTrials.gov ID: NCT04660760

COordinated Nivolumab and IntraperiToneal IL-2 for Gastric CanceR with PeritOneaL Metastasis (CONTROL) Phase 1b Pilot Study

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with gastric or GEJ adenocarcinoma limited to peritoneal metastases (PCI 1–24), ECOG 0–2, starting or on first-line FOLFOX plus nivolumab without progression. Adds intraperitoneal aldesleukin (IL-2; immune-stimulatory cytokine activating T cells/NK cells) on days 1 and 8 of each 14‑day cycle with standard FOLFOX+nivolumab to reduce peritoneal disease; excludes non-peritoneal mets and prior checkpoint/IL-2.

ClinicalTrials.gov ID: NCT05802056

A Phase II Study Of Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Overexpressing Gastroesophageal Cancers

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with previously untreated, HER2-overexpressing/metastatic esophageal, gastric, or GEJ adenocarcinoma (IHC 3+ or FISH+ if IHC 2+), ECOG 0–1, receive neratinib (irreversible pan-HER TKI targeting EGFR/HER2/HER4) added to mFOLFOX plus trastuzumab and pembrolizumab; treated/stable brain metastases allowed. Excludes active CNS disease, significant cardiac disease, >grade 1 neuropathy, active autoimmune disease on systemic therapy, pneumonitis, active infection, or chronic steroids >10 mg prednisone equivalent.

ClinicalTrials.gov ID: NCT06109467

Nivolumab and CAPOX in Patients With FGFR2/PD-L1-positive Metastatic Gastric Adenocarcinoma: a Single-arm, Phase 2 Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with untreated, unresectable/metastatic, HER2-negative gastric adenocarcinoma that is PD-L1 CPS ≥5 and FGFR2-overexpressing (IHC ≥2+) receive nivolumab (PD-1 inhibitor) plus CAPOX every 3 weeks. Key endpoints include 1-year PFS with secondary ORR, PFS, OS, and safety; excludes active CNS metastases and viral hepatitis/HIV.

ClinicalTrials.gov ID: NCT05859477

A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves adults with unresectable or metastatic advanced solid tumors who have progressed on prior treatments or are candidates for pembrolizumab, combining pembrolizumab, which targets the PD-1 receptor to enhance immune response, with a personalized neoantigen peptide vaccine designed to stimulate an individualized immune attack against tumor-associated proteins.

ClinicalTrials.gov ID: NCT05269381

A Phase 1, Multicenter, Open-label, Dose-escalation Study Evaluating the Safety and Tolerability of Intravenous KK2269 Monotherapy and Combination Therapy With Docetaxel in Adult Participants With Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with advanced solid tumors, focusing on gastric, GEJ, esophageal adenocarcinomas, and NSCLC, testing KK2269, a bispecific antibody targeting CD40 and EpCAM, alone and in combination with docetaxel to assess safety and tolerability.

ClinicalTrials.gov ID: NCT06266299

A Phase 1/1b Study of IAM1363 in Patients with Advanced Cancers Harboring HER2 Alterations

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial evaluates IAM1363, an oral, irreversible tyrosine kinase inhibitor targeting HER2 mutations, in adult patients with advanced cancers harboring HER2 alterations who have relapsed or are intolerant to previous therapies, including a subgroup with brain metastases.

ClinicalTrials.gov ID: NCT06253871

A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplifications

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring KRAS mutations (excluding G12R) or KRAS amplification, testing the investigational oral pan-KRAS inhibitor BGB-53038 as monotherapy or in combination with tislelizumab (for nonsquamous NSCLC) or cetuximab (for colorectal cancer). BGB-53038 selectively targets KRAS-mutated or amplified tumors, while sparing NRAS and HRAS.

ClinicalTrials.gov ID: NCT06585488

A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with advanced or recurrent HER2-expressing solid tumors (IHC 3+ or 2+/ISH+) who have exhausted standard therapy options are eligible to receive XMT-2056, a novel HER2-targeted antibody-drug conjugate with a STING agonist payload designed to activate tumor and immune cell STING pathways and induce ADCC.

ClinicalTrials.gov ID: NCT05514717

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Selected Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic GPC3-expressing solid tumors (including hepatocellular carcinoma, AFP-producing gastric cancer, extragonadal yolk sac tumors, non-dysgerminomas, or GPC3-positive squamous NSCLC) who have ECOG 0-1. Patients will receive the investigational bispecific antibody BGB-B2033 (targeting GPC3 and 4-1BB) alone or combined with the anti-PD-1 antibody tislelizumab.

ClinicalTrials.gov ID: NCT06427941